Zacks Research Has Optimistic Outlook of CRSP Q2 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Investment analysts at Zacks Research boosted their Q2 2025 earnings estimates for shares of CRISPR Therapeutics in a research note issued to investors on Tuesday, March 4th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of ($1.61) for the quarter, up from their previous forecast of ($1.65). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share. Zacks Research also issued estimates for CRISPR Therapeutics’ Q3 2025 earnings at ($1.42) EPS, Q4 2025 earnings at ($1.28) EPS, FY2025 earnings at ($5.90) EPS, Q1 2026 earnings at ($1.46) EPS, Q2 2026 earnings at ($1.44) EPS, Q3 2026 earnings at ($1.18) EPS, Q4 2026 earnings at ($1.09) EPS and FY2026 earnings at ($5.16) EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%.

A number of other equities analysts have also issued reports on CRSP. Morgan Stanley raised their price target on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an “underweight” rating in a research report on Friday, February 14th. Chardan Capital reduced their price target on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. Needham & Company LLC reissued a “buy” rating and set a $84.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, February 12th. Evercore ISI raised shares of CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and raised their price target for the stock from $60.00 to $99.00 in a research report on Friday, February 14th. Finally, Royal Bank of Canada reduced their price target on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a research report on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, CRISPR Therapeutics currently has an average rating of “Hold” and an average price target of $74.40.

CRISPR Therapeutics Trading Up 0.9 %

CRSP opened at $43.84 on Thursday. CRISPR Therapeutics has a 12-month low of $36.52 and a 12-month high of $83.50. The firm has a market capitalization of $3.76 billion, a PE ratio of -10.03 and a beta of 1.67. The firm has a 50 day moving average of $42.57 and a two-hundred day moving average of $45.86.

Insider Activity at CRISPR Therapeutics

In related news, Director John Greene acquired 7,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Wednesday, February 26th. The shares were purchased at an average cost of $44.85 per share, for a total transaction of $313,950.00. Following the acquisition, the director now owns 7,000 shares in the company, valued at approximately $313,950. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Samarth Kulkarni sold 18,360 shares of the business’s stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the sale, the chief executive officer now owns 171,613 shares in the company, valued at approximately $9,473,037.60. This trade represents a 9.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.10% of the stock is owned by insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

Several institutional investors have recently bought and sold shares of CRSP. ARK Investment Management LLC grew its position in CRISPR Therapeutics by 19.7% in the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock valued at $353,180,000 after acquiring an additional 1,474,439 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its position in CRISPR Therapeutics by 39.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company’s stock valued at $150,029,000 after acquiring an additional 1,074,238 shares in the last quarter. Capital International Investors grew its position in CRISPR Therapeutics by 10.3% in the 4th quarter. Capital International Investors now owns 8,743,523 shares of the company’s stock valued at $344,145,000 after acquiring an additional 816,789 shares in the last quarter. Baker BROS. Advisors LP grew its position in CRISPR Therapeutics by 743.1% in the 3rd quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company’s stock valued at $39,608,000 after acquiring an additional 743,075 shares in the last quarter. Finally, State Street Corp grew its position in CRISPR Therapeutics by 25.0% in the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock valued at $140,611,000 after acquiring an additional 599,304 shares in the last quarter. 69.20% of the stock is owned by institutional investors and hedge funds.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.